Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.

NCT02595320 is registered in ClinicalTrials.gov with Qamar Khan as lead sponsor.

NCT NCT02595320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.
Lead sponsor
Qamar Khan
Phase
Phase 2
Overall status
Unknown status
Start date
October 5, 2015
Completion date
December 31, 2023
Enrollment
200 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer